IRWD · XBRL financial data

Ironwood Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRWD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	390	414	411	443	351	296
Cost of goods and services sold	3	—	—	—	—	—
Research and development	88	70	44	116	111	95
Selling, general and administrative	140	111	116	158	144	82
Operating income (loss)	143	232	250	(945)	93	99
Interest expense	29	31	8	22	33	33
Other income (expense)	—	—	—	—	1	0
Income tax expense (benefit)	3	(328)	77	83	64	46
Net income (loss)	106	528	175	(1,002)	1	24
Earnings per share, basic USD per share	0.67	3.26	1.13	(6.45)	0.01	0.15
Earnings per share, diluted USD per share	0.66	3.21	0.96	(6.45)	0.01	0.15
Weighted average shares, basic millions of shares	159	162	154	155	159	162
Weighted average shares, diluted millions of shares	161	164	186	155	160	163

Fiscal years (IRWD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	363	620	656	92	89	215
Accounts receivable	122	114	115	129	82	47
Prepaid and other current assets	9	9	8	12	12	12
Total current assets	496	745	781	233	182	274
Property and equipment, net	9	8	6	6	4	3
Right-of-use asset	17	15	14	13	11	9
Total assets	559	1,127	1,101	471	351	397
Accounts payable	1	1	0	8	2	3
Total current liabilities	32	162	26	276	39	242
Lease liability, non-current	20	18	17	15	12	10
Total liabilities	—	—	—	—	—	659
Accumulated deficit	(1,466)	(938)	(696)	(1,699)	(1,698)	(1,674)
Total stockholders' equity	63	606	652	(346)	(301)	(262)
Total liabilities and equity	559	1,127	1,101	471	351	397
Common shares outstanding (cover page) millions of shares	161	159	154	157	162	163

Fiscal years (IRWD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	106	528	175	(1,002)	1	24
Stock-based compensation	31	22	27	32	30	17
Depreciation and amortization	2	2	1	1	1	1
Net cash from operating activities	169	262	274	183	104	127
Purchases of property and equipment	2	0	0	0	0	0
Net cash from investing activities	(2)	(0)	(0)	(1,026)	(0)	(0)
Share repurchases	—	24	126	—	—	—
Net cash from financing activities	19	(5)	(238)	277	(107)	0
Net change in cash	186	257	36	(566)	(4)	127

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ironwood Pharmaceuticals	79	113	58*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Vaxart	51	27	2.8*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	48	not reported	(11)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41	18	0.1*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	170	0.6	(23)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26	not reported	(9.6)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32	not reported	(15)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	148	0	(21)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13	not reported	(2.4)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.